MEDTRONIC IRELAND ENDURANT IIS BIFURCATED STENT GRAFT; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TR
|
Back to Search Results |
|
Model Number ESBF2814C103E |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problem
Abdominal Pain (1685)
|
Event Date 10/22/2023 |
Event Type
Injury
|
Event Description
|
A endurant iis stent graft system was implanted in a evar procedure. it was reported that post-operatively 20 days later, the patient experienced abdominal pain with unknown etiology in the periumbilical region, which was aggravated by eating and palpation.A ct of the abdomen and pelvis was performed, which had no definite findings.The patient was hospitalized and was put on a treatment of new medications (analgesics, laxatives, steroids, antiemetic, ppi medications).A egd (esophageal gastroduodenoscopy) was also performed.The hospitalization ended 3 days later and the event resolved.The investigator had the opinion that the pain was possibly a reaction of the stent graft with the thrombus in the aneurysm sac.It was reported that after the egd was performed, it was suggested that the pain could be secondary to peptic ulcer disease.The site (investigator) assessed the abdominal pain as having a possible relationship to the study procedure ,study device, and an underlying condition or disease.The sponsor assessed the pain as not related to the study device, possible related to the study procedure and possibly related to a underlying condition or disease.No additional clinical sequelae were provided and the patient is fine.
|
|
Manufacturer Narrative
|
Continuation of d10: section d information references the main component of the system.Other relevant device(s) are: product id: e tlw1610c146e, serial/lot #: (b)(6), ubd: 26-jun-2024, udi#: (b)(4) ; product id: etlw1610c124e, serial/lot #: (b)(6), ubd: 06-apr-2025, udi#: (b)(4).Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Search Alerts/Recalls
|
|
|